Braskem's 3-Year Slide Is Now a Balance-Sheet Story: Why I'd Wait

Creditor backing is still missing, and that keeps priority #1

A restructuring plan only matters if lenders believe it can happen. By that test, Braskem still has not cleared the bar.

Creditors rejected the core proposal behind Braskem's planned out-of-court deal, and later talks again fell short of the backing needed to keep the process moving. Creditors had rejected the financial restructuring proposal underpinning that effort, and negotiations again failed with at least one-third of the roughly R$50 billion debt Braskem intends to restructure. That threshold matters because Braskem still needs broad enough creditor support to advance its initial plan. Until that changes, the out-of-court narrative remains unproven.

That distrust is also showing up in the shares. Braskem's $3.7 billion debt restructuring plan was meant to strengthen confidence, but the stock still looks dominated by balance-sheet risk. The local listing has fallen 46.3% from its peak, and the ADR recorded a 12.50% decline that brought it near $2.79 support. With fewer than 30 days left under court-ordered interim protection, investors are no longer treating this as a simple cycle-recovery trade. They want evidence that Braskem can secure workable creditor terms first.

Braskem's operating case still depends on a spread recovery

The business side is not offering an easy reason to look past the capital structure.

The bull case is mainly a polymer-spread call

The bullish argument is not really about how Braskem operates today. It depends on a forecast that polymer prices recover, margins expand, and the business eventually reaches roughly $1 billion of sustainable post-reorganization EBITDA after a plan built on improving polymers prices and margins through to 2035. In other words, investors would be betting on better market conditions as much as on execution.

That makes valuation tricky. Even after the selloff, Braskem still trades at about 5.0x enterprise value against post-reorganization EBITDA. In a petrochemical name, that is not automatically cheap. If spread recovery arrives slowly or stays incomplete, the story shifts quickly from turnaround potential to distressed math.

Current demand still looks soft

Braskem's own restructuring document points to polymer spreads that have fallen sharply and are only projected to recover gradually. That is not the profile of a business coming off a strong demand rebound. It is the profile of a company asking investors to trust better pricing power later while today's operating backdrop remains weak.

Liquidity leaves little room for error

Braskem had only $911 million in cash as of April, while it still faces about $3.69 billion in debt service through year-end 2027. That is the main reason operating softness matters so much now: with limited liquidity and large near-term cash demands, the company has little room for mistakes.

The rating action underlines the pressure. Agencies cut Braskem to a default-equivalent rating after court relief allowed it to suspend debt payments for 60 days, with S&P downgrading the debt CCC- to D and Fitch describing the situation as a process similar to a default. For investors, that raises the hurdle: this is no longer just a cycle question. It is a credibility and capital-structure question first.

Why I'd wait for firmer terms, not a better story

Braskem says negotiations have involved only indicative, non-binding proposals. At the same time, reports say creditors are still pressing for terms such as asset-backed new financing. Management says operations remain normal, but the gap between the company and its creditors is still wide enough to keep risk elevated.

A rerating is possible if spreads improve faster than expected and consensual financing terms start to harden. But until creditor support becomes more concrete and the operating backdrop looks firmer, I'd wait. For now, the balance-sheet story still dominates everything else.